中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 7
Jul.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(7): 1597-1606

Efficacy and safety of pegylated interferon α-2b in treatment of patients with hepatitis B virus-related compensated liver cirrhosis: A real-world study

DOI: 10.12449/JCH260716
  • 1.

    Department of Hepatology，Third People’s Hospital of Taiyuan，Taiyuan 030021，China

  • 2.

    Department of Infectious Diseases，Tangdu Hospital，Air Force Medical University，Xi’an 710038，China

Research funding:

Clinical Research Special Fund of Wu Jieping Medical Foundation (320.6750.2022-06-30)

More Information
  • Corresponding author: Wang Qianhui， wangqianhui12345@126.com （ORCID： 0009-0002-9925-0896）
  • Received Date: 2025-12-10
  • Accepted Date: 2026-02-10
  • Published Date: 2026-07-25
    Abstract
  •   Objective  To investigate the antiviral efficacy of pegylated interferon α-2b （PEG-IFN-α-2b） in patients with HBV-related liver cirrhosis， to assess the safety and tolerability of this regimen， and to provide evidence-based medical evidence for optimizing the treatment strategies for patients with HBV-related compensated liver cirrhosis.  Methods  A prospective study was conducted among 115 patients with HBV-related compensated liver cirrhosis and 114 patients with CHB who attended Third People’s Hospital of Taiyuan from January 2023 to March 2024. Treatment-naïve patients received PEG-IFN-α-2b monotherapy， while the patients once treated with nucleos（t）ide analogues （NAs） received PEG-IFN-α-2b add-on therapy. The patients with HBV-related compensated liver cirrhosis were followed up at baseline and at 12， 24， 36， and 48 weeks of treatment. Samples were collected from CHB patients at baseline and at the end of follow-up to assess virological indicators， routine blood test results， and liver function. The chi-square test was used for comparison of categorical data between groups； the independent samples t-test was used for comparison of normally distributed continuous data between two groups， and the one-way repeated measures analysis of variance was used for comparison among different time ponts within the same group，and the Bonferroni was applied for post-hoc pairwise comparisons； the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups， and the Friedman test was used for comparison across different time points within the same group， and the Nemenyi test was utilized for subsequent pairwise comparisons. The multivariate stepwise Logistic regression analysis was used to investigate the influencing factors for clinical cure.  Results  Compared with the CHB group， the HBV-related compensated liver cirrhosis group had a significantly higher mean age （43.50±9.97 years vs 40.90±8.16 years， t=2.160， P=0.032）， a significantly higher proportion of patients with hepatitis B e antigen at baseline （28.70% vs 15.79%， χ2=4.788， P=0.029）， and a significantly lower platelet level ［（178.67±55.07）×109/L vs （194.93±55.79）×109/L， t=2.217， P=0.028］. Compared with the CHB group at the end of follow-up， the HBV-related compensated liver cirrhosis group had significantly lower HBV surface antigen （HBsAg） clearance rate （10.38% vs 33.04%， χ2=14.988， P<0.001） and HBV surface antibody positive rate （0.00% vs 19.64%， χ2 =21.041， P<0.001）. Compared with the CHB group at the end of follow-up，the HBV-related compensated liver cirrhosis group had significantly lower aminotransferase levels ［ALT： 31.00（19.00～47.50） U/L vs 40.00（27.00～57.00） U/L， Z=2.433， P<0.05； AST： 31.00（23.00～45.50） U/L vs 37.00（25.00～52.00） U/L， Z=1.963， P<0.05］， but significantly higher level of white blood cells （WBC） ［（4.02±1.56）×109/L vs （3.59±1.24）×109/L， t=2.272， P<0.05］， neutrophils ［（2.39±1.17）×109/L vs （1.87±0.94）×109/L， t=3.284， P<0.05］， and platelets ［（143.93±68.10）×109/L vs （121.88±49.72）×109/L， t=2.588， P<0.05］. A lower level of HBsAg （OR=0.997， 95%CI： 0.996　—　0.999， P<0.001） and previous treatment with NAs （OR=5.889， 95%CI： 2.195　—　17.330， P<0.001） were positive predictive factors for clinical cure， while liver cirrhosis （OR=0.177， 95%CI： 0.063　—　0.470， P<0.001） was a negative predictive factor for clinical cure. During follow-up， no patients experienced acute decompensation or progression to hepatocellular carcinoma， and the main adverse events included fever， fatigue， reductions in WBC and platelets， weight loss， alopecia， and thyroid dysfunction. In the subgroup analysis of HBV-related compensated liver cirrhosis， in both the treatment-naïve patients and the patients previously treated with NAs， there was a significant reduction in HBsAg level from baseline to week 36 of treatment ［treatment-naïve： 99.25 （5.87　—　1 212.35） IU/mL vs 403.47 （36.94　—　2 569.02） IU/mL， P<0.05； previously treated with NAs： 205.94 （14.00　—　737.80） IU/mL vs 427.03 （65.64　—　1 552.65） IU/mL， P<0.05］ and week 48 of treatment ［treatment-naïve： 85.45 （0.58　—　827.56） IU/mL vs 403.47 （36.94　—　2 569.02） IU/mL， P<0.05； previously treated with NAs： 45.28 （0.16　—　267.27） IU/mL vs 427.03 （65.64　—　1 552.65） IU/mL， P<0.05］. There were significant increases in the levels of aminotransferases during treatment， as well as significant reductions in the levels of WBC， neutrophils， platelets， and hemoglobin （all P<0.05）.  Conclusion  Although a finite course of PEG-IFN-α-2b therapy has achieved a relatively low rate of clinical cure in the treatment of HBV-related compensated liver cirrhosis， it can still significantly reduce the level of HBsAg， and this treatment regimen has good safety and tolerability， without accelerating disease progression.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    Cui F Q, Shen L P, Li L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23( 5): 765- 772. DOI: 10.3201/eid2305.161477.
    [2]
    Liu J, Liang W N, Jing W Z, et al. Countdown to 2030: Eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97( 3): 230- 238. DOI: 10.2471/BLT.18.219469.
    [3]
    Cao G Y, Liu J, Liu M. Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: Findings from the Global Burden of Disease Study[J]. Chin Med J, 2022, 135( 17): 2049- 2055. DOI: 10.1097/CM9.0000000000002331.
    [4]
    Moini M, Fung S. HBsAg loss as a treatment endpoint for chronic HBV infection: HBV cure[J]. Viruses, 2022, 14( 4): 657. DOI: 10.3390/v14040657.
    [5]
    Yeo Y H, Ho H J, Yang H I, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: A systematic review and meta-analysis[J]. Gastroenterology, 2019, 156( 3): 635- 646. DOI: 10.1053/j.gastro.2018.10.027.
    [6]
    Zhang Yang, Li Yongsheng, Wang Jing. Effect of ganfule capsule,tenofovir amibufenamide tablets combined with polyethylene glycol interferon α-2b in patients with chronic hepatitis B and its influence on immune function[J]. J Clin Exp Med, 2024, 23( 21): 2268- 2271. DOI: 10.3969/j.issn.1671-4695.2024.21.008.

    张阳, 李永胜, 王婧. 肝复乐胶囊、艾米替诺福韦片联合聚乙二醇干扰素α-2b治疗慢性乙型病毒性肝炎的临床疗效及对免疫功能的影响[J]. 临床和实验医学杂志, 2024, 23( 21): 2268- 2271. DOI: 10.3969/j.issn.1671-4695.2024.21.008.
    [7]
    Hu P, Shang J, Zhang W H, et al. HBsAg loss with peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: New switch study[J]. J Clin Transl Hepatol, 2018, 6( 1): 25- 34. DOI: 10.14218/JCTH.2017.00072.
    [8]
    Wu F P, Yang Y, Li M, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen≤1500 IU/mL: An observational study[J]. World J Gastroenterol, 2020, 26( 13): 1525- 1539. DOI: 10.3748/wjg.v26.i13.1525.
    [9]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [10]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(2022 version)[J]. Chin J Infect Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
    [11]
    Ning Q, Han M F, Sun Y T, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial(OSST trial)[J]. J Hepatol, 2014, 61( 4): 777- 784. DOI: 10.1016/j.jhep.2014.05.044.
    [12]
    Han C, Jin L L, Zhu M J, et al. Efficacy and predictors of pegylated-interferon in hepatitis B surface antigen seroclearance in immune active and inactive chronic hepatitis B patients[J]. J Virus Erad, 2025, 11( 4): 100616. DOI: 10.1016/j.jve.2025.100616.
    [13]
    García-López M, Lens S, Pallett L J, et al. HBV suppression by nucleos(t)ide analogues reduces PD-1 expression on liver-resident T cells[J]. Liver Int, 2025, 45( 11): e70338. DOI: 10.1111/liv.70338.
    [14]
    Khanam A, Chua JV, Kottilil S. Immunopathology of chronic hepatitis B infection: Role of innate and adaptive immune response in disease progression[J]. Int J Mol Sci, 2021, 22( 11): 5497. DOI: 10.3390/ijms22115497.
    [15]
    Huang Y, Qi M, Liao C J, et al. Analysis of the efficacy and safety of PEGylated interferon-α2b treatment in inactive hepatitis B surface antigen carriers[J]. Infect Dis Ther, 2021, 10( 4): 2323- 2331. DOI: 10.1007/s40121-021-00511-w.
    [16]
    Cao Z H, Liu Y L, Ma L N, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J]. Hepatology, 2017, 66( 4): 1058- 1066. DOI: 10.1002/hep.29213.
    [17]
    Ren H, Huang Y. Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B[J]. J Viral Hepat, 2019, 26( Suppl 1): 5- 31. DOI: 10.1111/jvh.13150.
    [18]
    Bai Q Q, Li R Y, He X, et al. Single-cell landscape of immune cells during the progression from HBV infection to HBV cirrhosis and HBV-associated hepatocellular carcinoma[J]. Front Immunol, 2023, 14: 1320414. DOI: 10.3389/fimmu.2023.1320414.
    [19]
    Sun R N, Li J W, Lin X Y, et al. Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma[J]. Front Immunol, 2023, 14: 1079495. DOI: 10.3389/fimmu.2023.1079495.
    [20]
    Qin Lei, Li Guangpeng, Shen Peijun, et al. Effect of pegylated interferon-α-2b therapy on cytotoxicity of virus-specific CD8+ T cells in HBeAg-negative patients with chronic hepatitis B virus infection[J]. J Clin Hepatol, 2025, 41( 4): 628- 636. DOI: 10.12449/JCH250406.

    秦蕾, 李广鹏, 申培君, 等. 聚乙二醇干扰素-α-2b对HBeAg阴性慢性HBV感染者HBV特异性CD8+T淋巴细胞杀伤功能的影响[J]. 临床肝胆病杂志, 2025, 41( 4): 628- 636. DOI: 10.12449/JCH250406.
    [21]
    Lee H W, Yip T C, Tse Y K, et al. Hepatic decompensation in cirrhotic patients receiving antiviral therapy for chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2021, 19( 9): 1950- 1958. DOI: 10.1016/j.cgh.2020.08.064.
    [22]
    Yang D H, Wang W P, Zhang Q, et al. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside(acid) analogs therapy: A retrospective cross-sectional study[J]. World J Gastroenterol, 2021, 27( 17): 2025- 2038. DOI: 10.3748/wjg.v27.i17.2025.
    [23]
    Li S Y, Li H, Xiong Y L, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study[J]. J Viral Hepat, 2017, 24( Suppl 1): 12- 20. DOI: 10.1111/jvh.12755.
    [24]
    Erken R, Loukachov V V, de Niet A, et al. A prospective five-year follow-up after peg-interferon plus nucleotide analogue treatment or no treatment in HBeAg negative chronic hepatitis B patients[J]. J Clin Exp Hepatol, 2022, 12( 3): 735- 744. DOI: 10.1016/j.jceh.2021.12.011.
    [25]
    Mao Q G, Liang H Q, Yin Y L, et al. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B[J]. Clin Res Hepatol Gastroenterol, 2022, 46( 1): 101758. DOI: 10.1016/j.clinre.2021.101758.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(7)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (90) PDF downloads(20) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return